Premium
Inhibition of release of inflammatory mediators in rat peritoneal mast cells and murine macrophages by a chinese herbal medicine formula (RCM‐102)
Author(s) -
Le George Binh,
Xue Charlie Changli,
Story David Frederick,
Thien Francis Chung Kong,
Li Chun Guang
Publication year - 2009
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.2608
Subject(s) - histamine , lipopolysaccharide , pharmacology , nitric oxide , mast cell , prostaglandin e2 , prostaglandin d2 , nitric oxide synthase , medicine , prostaglandin , prostaglandin e , in vitro , immunology , chemistry , biochemistry
RCM‐102 is a Chinese herbal medicine formulation derived from a formula which was shown to be effective in treating seasonal allergic rhinitis (SAR) in a randomized placebo‐controlled trial. The aim of this study was to investigate the in vitro effect of RCM‐102 on the formation of inflammatory mediators, histamine, prostaglandin and nitric oxide, which are known to be involved in the pathophysiology of SAR. The effect of RCM‐102 on histamine release was tested in compound 48/80‐stimulated rat peritoneal mast cells. The effects of RCM‐102 on the release of NO and prostaglandins (PGE 2 ) and the expression of inducible NO synthase (iNOS) and COX‐2 were studied in lipopolysaccharide (LPS)‐stimulated RAW 264.7 cells. In rat peritoneal mast cells, RCM‐102 significantly reduced the compound 48/80‐induced histamine release. It also significantly reduced NO and PGE 2 production as well as the expression of COX‐2 and iNOS in RAW 264.7 cells. These findings indicate that RCM‐102 inhibits the formation of several allergic/inflammatory mediators and thus may be used for treating related conditions such as SAR. The actions of RCM‐102 are likely to be contributed by the synergistic actions of individual herbal ingredients. Copyright © 2009 John Wiley & Sons, Ltd.